| P2093 | author name string | K L Goa | |
| | C J Dunn | |
| P2860 | cites work | Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis | Q24299373 |
| | A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis | Q24308699 |
| | 5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes | Q24320095 |
| | The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock | Q24537753 |
| | Expression cloning of a cDNA for human leukotriene C4 synthase, an integral membrane protein conjugating reduced glutathione to leukotriene A4 | Q24564369 |
| | Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist | Q28319336 |
| | Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials | Q28344299 |
| | Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma | Q28369934 |
| | The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children | Q28370742 |
| | Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment | Q28371296 |
| | Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor | Q28371781 |
| | Churg-Strauss syndrome and antiasthma therapy | Q28373363 |
| | Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis | Q28377209 |
| | Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma | Q28377487 |
| | Efficacy and duration of action of the antileukotriene zafirlukast on cold air-induced bronchoconstriction | Q28377589 |
| | The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils | Q28622214 |
| | Characterization of the human cysteinyl leukotriene 2 receptor | Q30305734 |
| | Effectiveness and tolerability of zafirlukast for the treatment of asthma in children | Q31423025 |
| | Improving outcomes in elderly patients with asthma | Q33539475 |
| | Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial | Q33607514 |
| | Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis | Q33634936 |
| | Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma | Q33649671 |
| | Salmeterol tachyphylaxis in steroid treated asthmatic subjects | Q33775495 |
| | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers | Q33976257 |
| | Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group | Q33976334 |
| | Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast | Q34512391 |
| | Liberation of histamine and formation of lysocithin-like substances by cobra venom | Q34568156 |
| | Reference spirometric values using techniques and equipment that meet ATS recommendations | Q34717300 |
| | Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma | Q34745153 |
| | Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. | Q35532670 |
| | Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects | Q36138245 |
| | Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study | Q36244451 |
| | Tolerability of leukotriene modifiers in asthma: a review of clinical experience | Q37010100 |
| | Role of phospholipase in generating lipid second messengers in signal transduction | Q37326858 |
| | Mucosal inflammation in asthma | Q37946348 |
| | Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. | Q39473939 |
| | Guidelines update: where do the new therapies fit in the management of asthma? NHLBI and WHO Global Initiative for Asthma | Q40771507 |
| | Inhibition of leukotriene D4-induced bronchoconstriction in normal subjects by the oral LTD4 receptor antagonist ICI 204,219. | Q41199570 |
| | Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport | Q41204990 |
| | Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late-phase asthmatic reactions | Q41270215 |
| | Regulatory functions of phospholipase A2. | Q41514160 |
| | Salmeterol. A review of its pharmacological properties and clinical efficacy in the management of children with asthma | Q41563083 |
| | Third International Pediatric Consensus statement on the management of childhood asthma. International Pediatric Asthma Consensus Group | Q41706736 |
| | The mechanism of vascular leakage induced by leukotriene E4. Endothelial contraction | Q41881567 |
| | Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group | Q42284265 |
| | The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics | Q42285428 |
| | Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. | Q42286335 |
| | The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma | Q42288897 |
| | Potent leukotriene D4 receptor antagonist ICI 204,219 given by the inhaled route inhibits the early but not the late phase of allergen-induced bronchoconstriction | Q42288898 |
| | An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses | Q42536248 |
| | Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. | Q42537754 |
| | Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group | Q42546418 |
| | Combined antagonism of leukotrienes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics | Q42549036 |
| | Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. | Q42551235 |
| | Difficult asthma or Churg-Strauss syndrome? | Q42760743 |
| | Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids | Q43505948 |
| | The preclinical pharmacology of ICI 204,219. A peptide leukotriene antagonist | Q46786376 |
| | Preclinical exploration of the potential antiinflammatory properties of the peptide leukotriene antagonist ICI 204,219 (Accolate). | Q46879504 |
| | Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. | Q48793845 |
| | Leukotriene modifiers and Churg-Strauss syndrome: adverse effect or response to corticosteroid withdrawal? | Q52915928 |
| | Churg-Strauss syndome | Q53474239 |
| | Recombinant mouse leukotriene A4 hydrolase: a zinc metalloenzyme with dual enzymatic activities. | Q54295169 |
| | Leukotrienes are potent constrictors of human bronchi | Q59082833 |
| | Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma | Q68121522 |
| | Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects | Q68293935 |
| | Bronchoconstrictor effects of leukotriene C in humans | Q70298182 |
| | Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro | Q70469921 |
| | Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219 | Q70530056 |
| | Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol | Q71089909 |
| | Effects of leukotriene D on the airways in asthma | Q71655873 |
| | Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol | Q71736519 |
| | Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients | Q71897448 |
| | Comparison of patients' compliance with prescribed oral and inhaled asthma medications | Q71992470 |
| | Increases in 5-lipoxygenase activating protein expression account for enhanced capacity for 5-lipoxygenase metabolism that accompanies differentiation of peripheral blood monocytes into alveolar macrophages | Q72102588 |
| | Leukotriene E4 and granulocytic infiltration into asthmatic airways | Q72215711 |
| | Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol | Q72685455 |
| | Compliance with an oral asthma medication: a pilot study using an electronic monitoring device | Q72990585 |
| | Effects of 2 weeks of treatment with fluticasone propionate 100 mcg b.d. by comparison with zafirlukast 20 mg b.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma | Q73542145 |
| | Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) | Q73555000 |
| | A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge | Q73651100 |
| | Treatment preferences of adolescent patients with asthma | Q73684676 |
| | Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma | Q73900960 |
| | Antileukotrienes in chronic urticaria | Q74493362 |
| | Salmeterol compared with current therapies in chronic asthma | Q77467490 |
| | Steroids and Churg-Strauss syndrome | Q77506693 |
| | A six-month, placebo-controlled comparison of the safety and efficacy of salmeterol or beclomethasone for persistent asthma | Q77984791 |
| | Zafirlukast and Churg-Strauss syndrome | Q78054078 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| | pharmacology | Q128406 |
| | zafirlukast | Q928378 |
| P304 | page(s) | 285-315 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma | |
| P478 | volume | 61 | |